CR11537A - Vacuna - Google Patents
VacunaInfo
- Publication number
- CR11537A CR11537A CR11537A CR11537A CR11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A CR 11537 A CR11537 A CR 11537A
- Authority
- CR
- Costa Rica
- Prior art keywords
- viral vector
- vector
- seq
- relates
- malaria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a un vector adenovirico de simio deficiente de replicacion C7 que codifica una proteina CS de P. falciparum o un fragmento de la misma, por ejemplo como se muestra en la SEC ID N° 1 o la SEC ID N° 3. La invencion se refiere tambien a procedimientos de preparacion de dicho vector virico y al uso del vector virico en el tratamiento/prevencion de infeccion por la malaria. se describen tambien composiciones, vacunas y kits que comprenden dicho vector virico. En un aspecto, la invencion emplea un vector virico C7 sintetico. El vector virico C7 segun la invencion puede coadministrarse o coformularse con un antigeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99280207P | 2007-12-06 | 2007-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11537A true CR11537A (es) | 2010-08-18 |
Family
ID=40591828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11537A CR11537A (es) | 2007-12-06 | 2010-06-29 | Vacuna |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2227550A2 (es) |
| JP (1) | JP2011505796A (es) |
| KR (1) | KR20100108544A (es) |
| CN (1) | CN101939438A (es) |
| AR (1) | AR069568A1 (es) |
| AU (1) | AU2008333208A1 (es) |
| BR (1) | BRPI0819889A2 (es) |
| CA (1) | CA2707245A1 (es) |
| CL (1) | CL2008003614A1 (es) |
| CO (1) | CO6300795A2 (es) |
| CR (1) | CR11537A (es) |
| DO (1) | DOP2010000164A (es) |
| IL (1) | IL205953A0 (es) |
| MA (1) | MA32003B1 (es) |
| MX (1) | MX2010006207A (es) |
| PE (1) | PE20091106A1 (es) |
| TW (1) | TW200938633A (es) |
| UY (1) | UY31510A1 (es) |
| WO (1) | WO2009071613A2 (es) |
| ZA (1) | ZA201003851B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| JP6054942B2 (ja) * | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| US8232255B2 (en) * | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| WO2005063805A1 (en) * | 2003-12-23 | 2005-07-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection |
| PT1711518E (pt) * | 2004-01-23 | 2010-02-26 | Isti Di Ric Di Bio Moleco P An | Transportadores de vacinas de adenovírus de chimpanzé |
| JP5108521B2 (ja) * | 2004-10-14 | 2012-12-26 | クルセル ホランド ベー ヴェー | マラリア初回免疫／追加免疫ワクチン |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| MX2009000650A (es) * | 2006-07-18 | 2009-07-02 | Secretary Of The Army The Unit | Vacunas para malaria. |
| EA021391B1 (ru) * | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
-
2008
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Application Discontinuation
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en active Application Filing
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
-
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091106A1 (es) | 2009-08-24 |
| MX2010006207A (es) | 2010-10-04 |
| TW200938633A (en) | 2009-09-16 |
| JP2011505796A (ja) | 2011-03-03 |
| CL2008003614A1 (es) | 2010-01-15 |
| CN101939438A (zh) | 2011-01-05 |
| AR069568A1 (es) | 2010-02-03 |
| CO6300795A2 (es) | 2011-07-21 |
| BRPI0819889A2 (pt) | 2015-06-16 |
| WO2009071613A2 (en) | 2009-06-11 |
| IL205953A0 (en) | 2010-11-30 |
| WO2009071613A3 (en) | 2009-08-13 |
| DOP2010000164A (es) | 2010-07-31 |
| AU2008333208A1 (en) | 2009-06-11 |
| KR20100108544A (ko) | 2010-10-07 |
| EP2227550A2 (en) | 2010-09-15 |
| CA2707245A1 (en) | 2009-06-11 |
| UY31510A1 (es) | 2009-08-03 |
| ZA201003851B (en) | 2012-11-28 |
| MA32003B1 (fr) | 2011-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
| MX347997B (es) | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. | |
| TNSN07387A1 (en) | C.perfringens alpha toxoid vaccine | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| WO2007011904A3 (en) | Recombinant flu vaccines | |
| EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| PE20100658A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| MX340830B (es) | Vacuna neumococica y usos de la misma. | |
| WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| AR093712A1 (es) | Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| PE20080428A1 (es) | Vacunas para la malaria | |
| WO2008054535A3 (en) | Novel influenza m2 vaccines | |
| CR11307A (es) | Vacunas | |
| EA201290956A1 (ru) | Вакцина против вич | |
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| CR11537A (es) | Vacuna | |
| MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
| ZA202107428B (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
| TW200637573A (en) | Peptide for delivery of mucosal vaccines | |
| WO2018066999A3 (en) | Chimeric enterovirus virus-like particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |